Study Evaluating Antibiotic Use in Reducing Vancomycin-Resistant Enterococci and ESBL Producing Escherichia Coli and Klebsiella Pneumoniae in Intensive Care

Antibiotic Intervention Trial in a Medical Intensive Care Unit to Reduce the Acquisition of Vancomycin-Resistant Enterococci and ESBL Producing Escherichia Coli and Klebsiella Pneumoniae.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00167986

Enrollment

480

Registered

2005-09-14

Start date

2005-01-31

Completion date

Unknown

Last updated

2007-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Escherichia Coli Infections, Klebsiella Infections

Keywords

Bacterial Infections

Brief summary

To determine whether the restriction of 3rd generation cephalosporins and carbapenems contribute to the reduction of intestinal colonization or infection with vancomycin-resistant enterococci (VRE) in a medical intensive care unit (MICU).

Interventions

DRUGvancomycin-resistant enterococci and ESBL

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* All patients admitted to or transferred to the MICU. * Patients 18 years of age or older. * Provide written informed consent.

Exclusion criteria

* Patients known to be infected or colonized by VRE or ESBL-producing E.coli, K.pneumoniae. * Patients who have hypersensitivity to penicillin. * Any underlying conditions or diseases that will be ultimately fatal within 48 hours. * Any concurrent condition or medication which would interfere with absorption or metabolism of study drugs.

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026